Vaccine for Cervical Cancer Could Extend Survival in Relapsed Disease

Researchers are assessing the vaccine axalimogene filolisbac in patients at high risk of relapse.
Researchers are assessing the vaccine axalimogene filolisbac in patients at high risk of relapse.

An intravenous vaccine, axalimogene filolisbac, could prevent relapse of cervical cancer. Relapsed cervical cancer is frequently fatal.

Researchers are assessing the vaccine in patients at high risk of relapse. Axalimogene filolisbac helps the patient's own immune system better fight tumor cells targeting the E7 protein, a protein involved in both tumor and human papillomavirus (HPV) proliferation.

In this trial, two-thirds of participants will receive the vaccine every 3 weeks for 3 months, then every 8 weeks for 5 more doses, or until disease recurrence. The remaining one-third of participants will receive a placebo.

Target enrollment is 450 patients, and the trial will run worldwide, with follow-up planned for 3 to 5 years.

All study participants will have completed a course of the standard of care for cervical cancer.

The most common adverse events of axalimogene filolisbac are fever and flu-like symptoms.

Currently, a phase II trial of axalimogene filolisbac in patients with relapsed disease is examining whether the vaccine increases 12-month survival. Preliminary results from this trial indicate that the vaccine does indeed increase survival.

Reference

1. Therapeutic vaccine designed to reduce recurrence of cervical cancer under study [press release]. Augusta, GA: medical College of Georgia at Augusta University; April 25, 2017. https://www.eurekalert.org/pub_releases/2017-04/mcog-tvd042517.php. Accessed May 9, 2017.

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs